Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol

FASEB Journal

Volumn 22, Issue 6, 2008, Pages 1894-1904

  Puissant, Alexandre ^a,b,c   Grosso, Sebastien ^a,b,c   Jacquel, Arnaud ^a,b,c,d   Belhacene, Nathalie ^a,b,c   Colosetti, Pascal ^a,b,c   Cassuto, Jill Patrice ^c   Auberger, Patrick ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

^d Chu   (France)

Author keywords

Anticancer therapy; BCR ABL inhibitors; Caspase dependent cell death; Caspase independent cell death

Indexed keywords

BCR ABL PROTEIN; BENZYLOXYCARBONYL VALYLALALANYLASPARTIC ACID FLUOROMETHYL KETONE; CASPASE; IMATINIB; PHYTOALEXIN; POLYPEPTIDE; RESVERATROL;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG SENSITIVITY; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; STILBENES;

EID: 44949253057     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-101394     Document Type: Article

References (42)

1. Clarkson, B., and Strife, A. (1993) Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 7, 1683-1721
2. Groffen, J., Stephenson, J. R., Heisterkamp, N., de Klein, A., Bartram, C. R., and Grosveld, G. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36, 93-99
3. Ren, R. (2002) The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene 21, 8629-8642
4. Koschmieder, S., Gottgens, B., Zhang, P., Iwasaki-Arai, J., Akashi, K., Kutok, J. L., Dayaram, T., Geary, K., Green, A. R., Tenen, D. G., and Huettner, C. S. (2005) Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105, 324-334
5. Neering, S. J., Bushnell, T., Sozer, S., Ashton, J., Rossi, R. M., Wang, P. Y., Bell, D. R., Heinrich, D., Bottaro, A., and Jordan, C. T. (2007) Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 110, 2578-2585
6. Deininger, M. W., Goldman, J. M., and Melo, J. V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356
7. Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., and McCubrey, J. A. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18, 189-218
8. Jacquel, A., Herrant, M., Legros, L., Belhacene, N., Luciano, F., Pages, G., Hofman, P., and Auberger, P. (2003) Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J. 17, 2160-2162
9. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Regenass, U., and Lydon, N. B. (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U. S. A. 92, 2558-2562
10. Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., and Zigler, A. J. (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96, 925-932
11. Dan, S., Naito, M., and Tsuruo, T. (1998) Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ. 5, 710-715
12. Fang, G., Kim, C. N., Perkins, C. L., Ramadevi, N., Winton, E., Wittmann, S., and Bhalla, K. N. (2000) CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96, 2246-2253
13. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A. E., Capdeville, R., and Druker, B. J. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004
14. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042
15. Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., Ottmann, O. G., Schiffer, C. A., Talpaz, M., Guilhot, F., Deininger, M. W., Fischer, T., O'Brien, S. G., Stone, R. M., Gambacorti-Passerini, C. B., Russell, N. H., Reiffers, J. J., Shea, T. C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R. A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R. L., and Druker, B. J. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530-3539
16. Mahon, F. X., Deininger, M. W., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., and Melo, J. V. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070-1079
17. Le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., and Gambacorti-Passerini, C. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95, 1758-1766
18. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880
19. Mahon, F. X., Belloc, F., Lagarde, V., Chollet, C., Moreau-Gaudry, F., Reiffers, J., Goldman, J. M., and Melo, J. V. (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373
20. Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., and Talpaz, M. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690-698
21. Shen, M., Jia, G. L., Wang, Y. M., and Ma, H. (2006) Cardioprotective effect of resvaratrol pretreatment on myocardial ischemia-reperfusion induced injury in rats. Vascul. Pharmacol. 45, 122-126
22. Athar, M., Back, J. H., Tang, X., Kim, K. H., Kopelovich, L., Bickers, D. R., and Kim, A. L. (2007) Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 224, 274-283
23. Gao, X., Xu, Y. X., Divine, G., Janakiraman, N., Chapman, R. A., and Gautam, S. C. (2002) Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. J. Nutr. 132, 2076-2081
24. MacCarrone, M., Lorenzon, T., Guerrieri, P., and Agro, A. F. (1999) Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur. J. Biochem. 265, 27-34
25. Luzi, C., Brisdelli, F., Cinque, B., Cifone, G., and Bozzi, A. (2004) Differential sensitivity to resveratrol-induced apoptosis of human chronic myeloid (K562) and acute lymphoblastic (HSB-2) leukemia cells. Biochem. Pharmacol. 68, 2019-2030
26. Morotti, A., Cilloni, D., Pautasso, M., Messa, F., Arruga, F., Defilippi, I., Carturan, S., Catalano, R., Rosso, V., Chiarenza, A., Taulli, R., Bracco, E., Rege-Cambrin, G., Gottardi, E., and Saglio, G. (2006) NF-B inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line. Am. J. Hematol. 81, 938-945
27. Jacquel, A., Herrant, M., Defamie, V., Belhacene, N., Colosetti, P., Marchetti, S., Legros, L., Deckert, M., Mari, B., Cassuto, J. P., Hofman, P., and Auberger, P. (2006) A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysis. Oncogene 25, 781-794
28. Herrant, M., Jacquel, A., Marchetti, S., Belhacene, N., Colosetti, P., Luciano, F., and Auberger, P. (2004) Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 23, 7863-7873
29. Scherr, M., Battmer, K., Winkler, T., Heidenreich, O., Ganser, A., and Eder, M. (2003) Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101, 1566-1569
30. Van de Wetering, M., Oving, I., Muncan, V., Pon Fong, M. T., Brantjes, H., van Leenen, D., Holstege, F. C., Brummelkamp, T. R., Agami, R., and Clevers, H. (2003) Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 4, 609-615
31. Jacquel, A., Colosetti, P., Grosso, S., Belhacene, N., Puissant, A., Marchetti, S., Breittmayer, J. P., and Auberger, P. (2007) Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene 26, 2445-2458
32. Kohmura, K., Miyakawa, Y., Kawai, Y., Ikeda, Y., and Kizaki, M. (2004) Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. J. Cell. Physiol. 198, 370-376
33. Kawano, T., Horiguchi-Yamada, J., Iwase, S., Furukawa, Y., Kano, Y., and Yamada, H. (2004) Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it. Mol. Cell. Biochem. 258, 25-33
34. Rangatia, J., and Bonnet, D. (2006) Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia 20, 68-76
35. Rodrigue, C. M., Arous, N., Bachir, D., Smith-Ravin, J., Romeo, P. H., Galacteros, F., and Garel, M. C. (2001) Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation. Br. J. Haematol. 113, 500-507
36. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., and Lydon, N. B. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145
37. Horvath, Z., Murias, M., Saiko, P., Erker, T., Handler, N., Madlener, S., Jaeger, W., Grusch, M., Fritzer-Szekeres, M., Krupitza, G., and Szekeres, T. (2006) Cytotoxic and biochemical effects of 3,3′,4,4′,5,5′- hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. Exp. Hematol. 34, 1377-1384
38. Tsan, M. F., White, J. E., Maheshwari, J. G., and Chikkappa, G. (2002) Anti-leukemia effect of resveratrol. Leuk. Lymphoma 43, 983-987
39. Zang, M., Xu, S., Maitland-Toolan, K. A., Zuccollo, A., Hou, X., Jiang, B., Wierzbicki, M., Verbeuren, T. J., and Cohen, R. A. (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55, 2180-2191
40. Dasgupta, B., and Milbrandt, J. (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. U. S. A. 104, 7217-7222
41. Park, C. E., Kim, M. J., Lee, J. H., Min, B. I., Bae, H., Choe, W., Kim, S. S., and Ha, J. (2007) Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp. Mol. Med. 39, 222-229
42. Bhardwaj, A., Sethi, G., Vadhan-Raj, S., Bueso-Ramos, C., Takada, Y., Gaur, U., Nair, A. S., Shishodia, S., and Aggarwal, B. B. (2007) Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109, 2293-2302